Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Profit After Tax (2023 - 2025)

NewAmsterdam Pharma's Profit After Tax history spans 3 years, with the latest figure at -$74.9 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 18.72% year-over-year to -$74.9 million; the TTM value through Dec 2025 reached -$203.8 million, up 15.64%, while the annual FY2025 figure was -$203.8 million, 15.64% up from the prior year.
  • Profit After Tax for Q4 2025 was -$74.9 million at NewAmsterdam Pharma, down from -$72.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $19.9 million in Q4 2023 and bottomed at -$93.8 million in Q1 2024.
  • The 3-year median for Profit After Tax is -$40.8 million (2023), against an average of -$46.1 million.
  • The largest YoY upside for Profit After Tax was 64.68% in 2024 against a maximum downside of 563.5% in 2024.
  • A 3-year view of Profit After Tax shows it stood at $19.9 million in 2023, then crashed by 563.5% to -$92.2 million in 2024, then increased by 18.72% to -$74.9 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Profit After Tax are -$74.9 million (Q4 2025), -$72.0 million (Q3 2025), and -$17.4 million (Q2 2025).